Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Niemann-Pick type C disease
Biotech
Cyclo Therapeutics merges with longtime backer Rafael Holdings
Cyclo’s lead asset is Trappsol Cyclo, a formulation of hydroxypropyl beta cyclodextrin being evaluated in Niemann-Pick disease type C1.
James Waldron
Aug 22, 2024 8:50am
'Clinical intuition' led FDA advisors to back Zevra's rare disease med
Aug 5, 2024 10:35am
Orphazyme meme ends with $13M sale to satisfy bankruptcy court
May 16, 2022 6:06am
Roche-partnered Scenic nabs $31M to test 3 rare disease meds
Mar 10, 2022 10:12am
Orphazyme to assess strategic options after EU advisers nix drug
Feb 24, 2022 10:45am
Pfizer, NEA-backed rare disease startup bumps up Series A to $42M
Jul 25, 2016 10:32am
